{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T06:12:48Z","timestamp":1788415968115,"version":"build-2803163510"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82160148"],"award-info":[{"award-number":["82160148"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["lzujbky-2023-ct06"],"award-info":[{"award-number":["lzujbky-2023-ct06"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Upper tract urothelial carcinoma (UTUC) is uncommon and aggressive, and evidence for perioperative antibody-drug conjugate or immunotherapy remains limited. We report a 59-year-old man with biomarker-non-enriched high-risk ureteral UTUC treated with four cycles of toripalimab plus disitamab vedotin before planned surgery. Magnetic resonance urography, urine cytology, and ureteroscopic biopsy supported high-grade UTUC with glandular differentiation; CDX-2, villin, and \u03b2-catenin positivity prompted exclusion of a gastrointestinal primary. The biopsy showed HER2 0, TROP2 0, and low PD-L1 expression. Restaging MRI and endoscopy demonstrated reduced visible lesion extent; axial dimensions decreased from 3.68 \u00d7 2.69\u00a0cm to 2.14 \u00d7 1.55\u00a0cm. No formal RECIST 1.1 category was assigned because imaging was not standardized. The patient then underwent planned laparoscopic radical nephroureterectomy with bladder cuff excision. Final pathology showed poorly differentiated ureteral urothelial carcinoma with marked histological heterogeneity, staged ypT2Nx. Recovery was uneventful. At the latest follow-up on May 28, 2026, the patient remained well, and surveillance cystoscopy showed no evident intravesical abnormality. This case highlights the limited representativeness of pretreatment biopsy in UTUC. The observed lesion reduction is hypothesis-generating and should not be interpreted as evidence of clinical efficacy. Standardized response assessment and longer follow-up are required.<\/jats:p>","DOI":"10.3389\/fonc.2026.1857919","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T05:16:10Z","timestamp":1788412570000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Radical nephroureterectomy after toripalimab plus disitamab vedotin in biomarker-non-enriched upper tract urothelial carcinoma"],"prefix":"10.3389","volume":"16","author":[{"given":"Guohui","family":"Cheng","sequence":"first","affiliation":[{"name":"Department of Urology, The Second Hospital and Clinical Medical School, Lanzhou University","place":["Lanzhou, Gansu, China"]},{"name":"Institute of Urology, Gansu Province Clinical Research Center for Urinary System Diseases, The Second Hospital of Lanzhou University","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Urology, The Second Hospital and Clinical Medical School, Lanzhou University","place":["Lanzhou, Gansu, China"]},{"name":"Institute of Urology, Gansu Province Clinical Research Center for Urinary System Diseases, The Second Hospital of Lanzhou University","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rundong","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Urology, The Second Hospital and Clinical Medical School, Lanzhou University","place":["Lanzhou, Gansu, China"]},{"name":"Institute of Urology, Gansu Province Clinical Research Center for Urinary System Diseases, The Second Hospital of Lanzhou University","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongze","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Urology, The Second Hospital and Clinical Medical School, Lanzhou University","place":["Lanzhou, Gansu, China"]},{"name":"Institute of Urology, Gansu Province Clinical Research Center for Urinary System Diseases, The Second Hospital of Lanzhou University","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangbin","family":"Kong","sequence":"additional","affiliation":[{"name":"Department of Urology, The Second Hospital and Clinical Medical School, Lanzhou University","place":["Lanzhou, Gansu, China"]},{"name":"Institute of Urology, Gansu Province Clinical Research Center for Urinary System Diseases, The Second Hospital of Lanzhou University","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhilong","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Urology, The Second Hospital and Clinical Medical School, Lanzhou University","place":["Lanzhou, Gansu, China"]},{"name":"Institute of Urology, Gansu Province Clinical Research Center for Urinary System Diseases, The Second Hospital of Lanzhou University","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.eururo.2025.02.023","article-title":"European association of urology guidelines on upper urinary tract urothelial carcinoma: summary of the 2025 update","volume":"87","author":"Masson-Lecomte","year":"2025","journal-title":"Eur Urol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1097\/ju.0000000000003480","article-title":"Diagnosis and management of non-metastatic upper tract urothelial carcinoma: AUA\/SUO guideline","volume":"209","author":"Coleman","year":"2023","journal-title":"J Urol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.12.002","article-title":"Disitamab vedotin plus toripalimab in patients with locally advanced or metastatic urothelial carcinoma (RC48-C014): a phase Ib\/II dose-escalation and dose-expansion study","volume":"36","author":"Zhou","year":"2025","journal-title":"Ann Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2025.100637","article-title":"Efficacy and safety of DV in HER2-negative and HER2-low locally advanced or metastatic urothelial carcinoma: Results of a phase 2 study","volume":"6","author":"Yan","year":"2025","journal-title":"Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-21-2210","article-title":"Safety, efficacy, and biomarker analysis of toripalimab in patients with previously treated advanced urothelial carcinoma: Results from a multicenter phase II trial POLARIS-03","volume":"28","author":"Sheng","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2025.03.003","article-title":"Impact of histological subtypes\/divergent differentiation on clinicopathological and oncological outcomes for patients with upper tract urothelial carcinoma treated with radical nephroureterectomy: A comprehensive updated systematic review and meta-analysis","volume":"8","author":"Krajewski","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2020.06.024","article-title":"Diagnostic accuracy of ureteroscopic biopsy in predicting stage and grade at final pathology in upper tract urothelial carcinoma: Systematic review and meta-analysis","volume":"46","author":"Subiela","year":"2020","journal-title":"Eur J Surg Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2012.229","article-title":"Distinguishing primary adenocarcinoma of the urinary bladder from secondary involvement by colorectal adenocarcinoma: Extended immunohistochemical profiles emphasizing novel markers","volume":"26","author":"Rao","year":"2013","journal-title":"Mod Pathol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2025.100753","article-title":"Spatial expression of HER2, NECTIN4, and TROP-2 in muscle-invasive bladder cancer and metastases: Implications for pathological and clinical management","volume":"38","author":"Dernbach","year":"2025","journal-title":"Mod Pathol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/his.13710","article-title":"Concordance of PD-L1 expression in matched urothelial bladder cancer specimens","volume":"73","author":"de Jong","year":"2018","journal-title":"Histopathology"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-021-01168-7","article-title":"Phase I study of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors","volume":"24","author":"Xu","year":"2021","journal-title":"Gastric Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1699538","article-title":"Real-world efficacy and safety of disitamab vedotin monotherapy or in combination with PD-1 inhibitors in locally advanced or metastatic upper tract urothelial carcinoma: a multicenter retrospective study","volume":"16","author":"He","year":"2025","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2023.05.011","article-title":"Impact of variant histology on oncological outcomes in upper tract urothelial carcinoma: Results from the ROBUUST Collaborative Group","volume":"21","author":"Douglawi","year":"2023","journal-title":"Clin Genitourin Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-015-1715-0","article-title":"The prognostic impact of squamous and glandular differentiation for upper tract urothelial carcinoma patients after radical nephroureterectomy","volume":"34","author":"Tang","year":"2016","journal-title":"World J Urol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2008.07.003","article-title":"Sarcomatoid carcinoma of the upper urinary tract: Clinical outcome and molecular characterization","volume":"40","author":"Wang","year":"2009","journal-title":"Hum Pathol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2021.01.031","article-title":"Impact of high-intensity local treatment on overall survival in stage IV upper tract urothelial carcinoma","volume":"39","author":"Paciotti","year":"2021","journal-title":"Urol Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/bju.16836","article-title":"The role of primary tumour site surgery in metastatic UTUC: a systematic review and meta-analysis","volume":"136","author":"Cella","year":"2025","journal-title":"BJU Int"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1857919\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T05:16:14Z","timestamp":1788412574000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1857919\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":17,"alternative-id":["10.3389\/fonc.2026.1857919"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1857919","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"article-number":"1857919"}}